FINWIRES · TerminalLIVE
FINWIRES

最新消息:優諾製藥計劃向英國提交亨廷頓舞蹈症治療藥物的上市申請後,其股價上漲

By

-- (標題和第一段更新了最新的股價動態。) UniQure (QURE) 股價週四上漲超過 18%,此前該公司表示計劃在第三季度向英國提交 AMT-130 用於治療亨廷頓舞蹈症的上市許可申請。 該公司表示,該計劃是在與英國藥品和保健產品監管局 (MHRA) 舉行預申請會議後製定的。 該公司還表示,已獲准在第二季與美國食品藥物管理局 (FDA) 舉行 B 類會議,預計將討論潛在的 III 期臨床試驗設計的關鍵要素。 該公司表示,正在國際市場上尋求 AMT-130 註冊的其他監管途徑,並預計將在下半年提供更多更新資訊。

Price: $19.82, Change: $+3.09, Percent Change: +18.47%

Related Articles

Mining & Metals

Eldorado Gold Q1 Adjusted Net Earnings Attributable to Holders US$188.2M, or $0.95 EPS

$ELD.TO
Research

Research Alert: Lpla Q1: Beats On Eps, Misses On Revenue, As Advisory Shift Improves Margins

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LPLA delivered Q1 2026 results, with revenues surging 35% to $5.94B (missing estimates by $60M) and adj. EPS of $5.60 beating Street estimates by $0.13. The wealth management transformation accelerated with advisory revenue reaching $2.62B (+55%) and advisory assets growing to $1.39T (+42%), now representing 59.5% of total client assets. We believe LPLA's strategic shift toward fee-based services continues creating a more stable revenue base while improving operating leverage, with total advisory and brokerage assets reaching $2.34T (+30%). Management lowered the upper end of its 2026 core G&A outlook by $20M to $2.16B-$2.19B, including Commonwealth-related expenses. The Commonwealth acquisition remains on track for Q4 2026 completion with asset retention targeting 90% and updated run-rate EBITDA of $410M. With corporate cash of $567M and leverage at 1.86x, we expect LPLA maintains substantial financial flexibility for growth initiatives and plans to resume share repurchases with an estimated $125M in Q2 2026.

$LPLA
Research

Research Alert: Team: Results And Guidance Surpass Expectations As Cloud Growth Accelerates

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TEAM delivered a strong Q3 beat with non-GAAP EPS of $1.75 exceeding consensus by $0.41, while total revenue of $1.787B grew 32% Y/Y, surpassing expectations by $90M. Cloud revenues of $1.132B accelerated to 29% growth from 26% in Q2, while Data Center sales of $560.7M surged 44% Y/Y, reaccelerating from Q2's 20% growth. RPO growth accelerated again, up 37% Y/Y reaching $3.996B, demonstrating strengthening demand and larger customer commitments driven by its AI-powered System of Work strategy. Despite restructuring charges of $223.8M, non-GAAP operating margin expanded 800 bps Y/Y to 34%, while free cash flow of $561.3M represented a 31% margin, up from Q2's 11%. Management raised FY 26 revenue growth guidance to 24% from 22%, with operating margin guidance improving to 29% from 25.5%. We view the balanced growth across Cloud migration and Data Center expansion as positive, demonstrating TEAM's ability to optimize customer transitions while maintaining strong operational leverage.

$TEAM